Proliferating cell nuclear antigen and mitotic activity in rectal cancer

Predictor of response to preoperative irradiation

Christopher G. Willett, Gretchen Warland, Robert Cheek, John Coen, Jimmy Efird, Paul C. Shellito, Carolyn Compton

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Purpose: This study examines the association between the pathologic response of rectal cancer after irradiation and its pretreatment proliferative state as assayed by proliferating cell nuclear antigen (PCNA) and mitotic activity. Patients and Methods: Ninety patients with clinical stage T3 and T4 rectal cancer received preoperative irradiation followed by surgery. Pretreatment tumor biopsies were scored for PCNA activity (number of tumor cells staining immunohistochemically with an anti-PCNA monoclonal antibody) and the number of mitoses per 10 high-powered fields (hpf). Postirradiation surgical specimens were examined for extent of residual disease. Results: The tumors of 33 of 90 patients (37%) exhibited marked pathologic downstaging (no residual tumor or cancer confined to the rectal wall) after preoperative irradiation. Two features were independently associated with the likelihood of marked pathologic regression after preoperative irradiation: lesion size and PCNA/mitotic activity. When stratified by tumor size, marked tumor regression occurred most frequently in smaller tumors with high PCNA/mitotic activity compared with larger tumors with lower PCNA/mitotic activity. Intermediate downstaging rates were seen for small or large tumors with moderate PCNA/mitotic activity. Conclusion: Tumor PCNA/mitotic activity predicts the likelihood of response to irradiation, which may aid in formulating treatment policies for patients with rectal cancer.

Original languageEnglish (US)
Pages (from-to)679-682
Number of pages4
JournalJournal of Clinical Oncology
Volume12
Issue number4
StatePublished - Apr 1994
Externally publishedYes

Fingerprint

Proliferating Cell Nuclear Antigen
Rectal Neoplasms
Neoplasms
Residual Neoplasm
Mitosis
Cell Count
Monoclonal Antibodies
Staining and Labeling
Biopsy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Proliferating cell nuclear antigen and mitotic activity in rectal cancer : Predictor of response to preoperative irradiation. / Willett, Christopher G.; Warland, Gretchen; Cheek, Robert; Coen, John; Efird, Jimmy; Shellito, Paul C.; Compton, Carolyn.

In: Journal of Clinical Oncology, Vol. 12, No. 4, 04.1994, p. 679-682.

Research output: Contribution to journalArticle

Willett, Christopher G. ; Warland, Gretchen ; Cheek, Robert ; Coen, John ; Efird, Jimmy ; Shellito, Paul C. ; Compton, Carolyn. / Proliferating cell nuclear antigen and mitotic activity in rectal cancer : Predictor of response to preoperative irradiation. In: Journal of Clinical Oncology. 1994 ; Vol. 12, No. 4. pp. 679-682.
@article{992e3d2a19364152b0073895f56ca8c3,
title = "Proliferating cell nuclear antigen and mitotic activity in rectal cancer: Predictor of response to preoperative irradiation",
abstract = "Purpose: This study examines the association between the pathologic response of rectal cancer after irradiation and its pretreatment proliferative state as assayed by proliferating cell nuclear antigen (PCNA) and mitotic activity. Patients and Methods: Ninety patients with clinical stage T3 and T4 rectal cancer received preoperative irradiation followed by surgery. Pretreatment tumor biopsies were scored for PCNA activity (number of tumor cells staining immunohistochemically with an anti-PCNA monoclonal antibody) and the number of mitoses per 10 high-powered fields (hpf). Postirradiation surgical specimens were examined for extent of residual disease. Results: The tumors of 33 of 90 patients (37{\%}) exhibited marked pathologic downstaging (no residual tumor or cancer confined to the rectal wall) after preoperative irradiation. Two features were independently associated with the likelihood of marked pathologic regression after preoperative irradiation: lesion size and PCNA/mitotic activity. When stratified by tumor size, marked tumor regression occurred most frequently in smaller tumors with high PCNA/mitotic activity compared with larger tumors with lower PCNA/mitotic activity. Intermediate downstaging rates were seen for small or large tumors with moderate PCNA/mitotic activity. Conclusion: Tumor PCNA/mitotic activity predicts the likelihood of response to irradiation, which may aid in formulating treatment policies for patients with rectal cancer.",
author = "Willett, {Christopher G.} and Gretchen Warland and Robert Cheek and John Coen and Jimmy Efird and Shellito, {Paul C.} and Carolyn Compton",
year = "1994",
month = "4",
language = "English (US)",
volume = "12",
pages = "679--682",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "4",

}

TY - JOUR

T1 - Proliferating cell nuclear antigen and mitotic activity in rectal cancer

T2 - Predictor of response to preoperative irradiation

AU - Willett, Christopher G.

AU - Warland, Gretchen

AU - Cheek, Robert

AU - Coen, John

AU - Efird, Jimmy

AU - Shellito, Paul C.

AU - Compton, Carolyn

PY - 1994/4

Y1 - 1994/4

N2 - Purpose: This study examines the association between the pathologic response of rectal cancer after irradiation and its pretreatment proliferative state as assayed by proliferating cell nuclear antigen (PCNA) and mitotic activity. Patients and Methods: Ninety patients with clinical stage T3 and T4 rectal cancer received preoperative irradiation followed by surgery. Pretreatment tumor biopsies were scored for PCNA activity (number of tumor cells staining immunohistochemically with an anti-PCNA monoclonal antibody) and the number of mitoses per 10 high-powered fields (hpf). Postirradiation surgical specimens were examined for extent of residual disease. Results: The tumors of 33 of 90 patients (37%) exhibited marked pathologic downstaging (no residual tumor or cancer confined to the rectal wall) after preoperative irradiation. Two features were independently associated with the likelihood of marked pathologic regression after preoperative irradiation: lesion size and PCNA/mitotic activity. When stratified by tumor size, marked tumor regression occurred most frequently in smaller tumors with high PCNA/mitotic activity compared with larger tumors with lower PCNA/mitotic activity. Intermediate downstaging rates were seen for small or large tumors with moderate PCNA/mitotic activity. Conclusion: Tumor PCNA/mitotic activity predicts the likelihood of response to irradiation, which may aid in formulating treatment policies for patients with rectal cancer.

AB - Purpose: This study examines the association between the pathologic response of rectal cancer after irradiation and its pretreatment proliferative state as assayed by proliferating cell nuclear antigen (PCNA) and mitotic activity. Patients and Methods: Ninety patients with clinical stage T3 and T4 rectal cancer received preoperative irradiation followed by surgery. Pretreatment tumor biopsies were scored for PCNA activity (number of tumor cells staining immunohistochemically with an anti-PCNA monoclonal antibody) and the number of mitoses per 10 high-powered fields (hpf). Postirradiation surgical specimens were examined for extent of residual disease. Results: The tumors of 33 of 90 patients (37%) exhibited marked pathologic downstaging (no residual tumor or cancer confined to the rectal wall) after preoperative irradiation. Two features were independently associated with the likelihood of marked pathologic regression after preoperative irradiation: lesion size and PCNA/mitotic activity. When stratified by tumor size, marked tumor regression occurred most frequently in smaller tumors with high PCNA/mitotic activity compared with larger tumors with lower PCNA/mitotic activity. Intermediate downstaging rates were seen for small or large tumors with moderate PCNA/mitotic activity. Conclusion: Tumor PCNA/mitotic activity predicts the likelihood of response to irradiation, which may aid in formulating treatment policies for patients with rectal cancer.

UR - http://www.scopus.com/inward/record.url?scp=0028261545&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028261545&partnerID=8YFLogxK

M3 - Article

VL - 12

SP - 679

EP - 682

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 4

ER -